Olverembatinib (HQP1351)
HQP1351SJ0003
Ascentage Pharma · Phase 1 · Recruiting · Enrollment 100
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Olverembatinib 30 to 50 mg every other day | SDH-deficient GIST (n = 26) | 30 to 50 mg | Single arm | n/r | partial response as best response: 23.1%, cutoff 11.13.2025median progression-free survival: 25.7 months, cutoff 11.13.2025 |